MedTrace Logo

Vitamin D3 Supplementation for Heart Failure Patients

NCT01636570 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-04-26

No results posted yet for this study

Summary

The purpose of this study is to determine if treatment with vitamin D3 of 10,000 International Units (IU) daily in vitamin D deficient patients for 6 months will improve B type natriuretic peptide (BNP), a marker of heart function, compared to placebo. The investigators also aim to determine if vitamin D helps cardiopulmonary function as evaluated by cardiopulmonary exercise test (CPX), laboratory values, strength, and quality of life in patients with stable congestive heart failure (Class II or III).

Conditions

Interventions

DRUG

Placebo Comparator: Sugar Pill

Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.

DRUG

Vitamin D3 (cholecalciferol)

10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.

Sponsors & Collaborators

  • Saint Patrick Hospital

    collaborator OTHER

  • Heidi Moretti, MS, RD

    lead OTHER

Principal Investigators

  • Bradley D Berry, MD · International Heart Institute of Montana

  • Heidi D Moretti, MS, RD · Saint Patrick Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01636570 on ClinicalTrials.gov